Sugar-free antibodies--the bacterial solution to autoimmunity?
- PMID: 19758213
- DOI: 10.1111/j.1749-6632.2009.04739.x
Sugar-free antibodies--the bacterial solution to autoimmunity?
Abstract
The enzyme EndoS from Streptococcus pyogenes is an immunomodulatory molecule hydrolyzing the conserved glycans in the effector part of immunoglobulin G (IgG). EndoS is remarkably specific for IgG, and hydrolysis has profound effects on IgG effector functions. EndoS pretreatment of IgG, or direct administration to animals with experimental antibody-mediated autoimmune diseases, inhibits development of disease or cures animals from established disease. The properties of EndoS make it a unique experimental tool and an attractive alternative to current therapies of conditions involving pathogenic antibodies. This review describes the discovery of EndoS, the effects of EndoS on IgG effector functions in vitro and in vivo, the biotechnological potential of EndoS, and the outcomes of EndoS treatment in animal models of autoimmunity.
Similar articles
-
Toward Clinical use of the IgG Specific Enzymes IdeS and EndoS against Antibody-Mediated Diseases.Methods Mol Biol. 2017;1535:339-351. doi: 10.1007/978-1-4939-6673-8_23. Methods Mol Biol. 2017. PMID: 27914091 Review.
-
Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen.J Autoimmun. 2012 Dec;39(4):304-14. doi: 10.1016/j.jaut.2012.04.002. Epub 2012 May 30. J Autoimmun. 2012. PMID: 22652418
-
In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner.Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15005-9. doi: 10.1073/pnas.0808248105. Epub 2008 Sep 24. Proc Natl Acad Sci U S A. 2008. PMID: 18815375 Free PMC article.
-
Therapeutic cleavage of IgG: new avenues for treating inflammation.Trends Immunol. 2008 Apr;29(4):173-8. doi: 10.1016/j.it.2008.01.007. Epub 2008 Mar 6. Trends Immunol. 2008. PMID: 18328782 Review.
-
EndoS from Streptococcus pyogenes is hydrolyzed by the cysteine proteinase SpeB and requires glutamic acid 235 and tryptophans for IgG glycan-hydrolyzing activity.BMC Microbiol. 2008 Jan 8;8:3. doi: 10.1186/1471-2180-8-3. BMC Microbiol. 2008. PMID: 18182097 Free PMC article.
Cited by
-
A facile synthesis of a complex type N-glycan thiazoline as an effective inhibitor against the antibody-deactivating endo-β-N-acetylglucosaminidases.J Carbohydr Chem. 2017;36(8-9):336-346. doi: 10.1080/07328303.2017.1403616. Epub 2017 Dec 7. J Carbohydr Chem. 2017. PMID: 30930529 Free PMC article.
-
Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy.Protein Cell. 2018 Jan;9(1):47-62. doi: 10.1007/s13238-017-0433-3. Epub 2017 Jun 8. Protein Cell. 2018. PMID: 28597152 Free PMC article. Review.
-
Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies.Biochim Biophys Acta. 2016 Aug;1860(8):1655-68. doi: 10.1016/j.bbagen.2016.04.016. Epub 2016 Apr 20. Biochim Biophys Acta. 2016. PMID: 27105835 Free PMC article. Review.
-
Full validation of therapeutic antibody sequences by middle-up mass measurements and middle-down protein sequencing.MAbs. 2016;8(2):318-30. doi: 10.1080/19420862.2015.1128607. Epub 2016 Jan 13. MAbs. 2016. PMID: 26760197 Free PMC article.
-
GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins.Nat Biotechnol. 2014 May;32(5):485-9. doi: 10.1038/nbt.2885. Epub 2014 Apr 20. Nat Biotechnol. 2014. PMID: 24752077 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
